Down-regulation of long non-coding RNA MEG3 promotes Schwann cell proliferation and migration and repairs sciatic nerve injury in rats

Yongbin Ma1,2,3 | Dongwang Zhai4 | Wenzhe Zhang1 | Huanyan Zhang3 | Liyang Dong5 | Yuepeng Zhou5 | Dingqi Feng1 | Yu Zheng1 | Ting Wang1 | Chaoming Mao5 | Xuefeng Wang1,3

1Department of Central Laboratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China
2Department of Pathogen Biology & Immunology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, China
3Department of Neurology Laboratory, Jintan Hospital, Jiangsu University, Jintan, China
4Department of Clinical Laboratory, Aerospace Center Hospital, Peking University, Beijing, China
5Department of Nuclear Medicine and Institute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

Abstract
Peripheral nerve injury and regeneration are complex processes and involve multiple molecular and signalling components. However, the involvement of long non-coding RNA (lncRNA) in this process is not fully clarified. In this study, we evaluated the expression of the lncRNA maternally expressed gene 3 (MEG3) in rats after sciatic nerve transection and explored its potential mechanisms. The expression of lncRNA MEG3 was up-regulated following sciatic nerve injury and observed in Schwann cells (SCs). The down-regulation of lncRNA MEG3 in SCs enhanced the proliferation and migration of SCs via the PTEN/PI3K/AKT pathway. The silencing of lncRNA MEG3 promoted the migration of SCs and axon outgrowth in rats after sciatic nerve transection and facilitated rat nerve regeneration and functional recovery. Our findings indicated that lncRNA MEG3 may be involved in nerve injury and injured nerve regeneration in rats with sciatic nerve defects by regulating the proliferation and migration of SCs. This gene may provide a potential therapeutic target for improving peripheral nerve injury.

Keywords
long non-coding RNA MEG3, migration, proliferation, Schwann cells, sciatic nerve transection
Peripheral nerve injury is a major clinical problem in adults due to its high disability and mortality.\(^1\) Although the peripheral nerve system (PNS) has axonal regeneration ability, PNS often shows an incomplete functional recovery following nerve injury.\(^2\) After this type of injury, the lesion site undergoes a series of pathophysiological alterations, including axonal degeneration and proliferation and migration of Schwann cells (SCs) to form Büngner bands, which provide a suitable microenvironment and facilitate axonal regeneration.\(^3,4\) However, the molecular mechanism of nerve injury and regeneration in PNS has not been fully clarified.

Non-coding RNAs (ncRNAs) especially long ncRNAs (lncRNAs) are differentially expressed in the central and peripheral nerve injury sites and possess regulatory roles in neural injury and regeneration.\(^5\) Zhao and colleagues reported that 322 lncRNAs are differentially expressed in hypoxic-ischemic brains, and the BC088414 lncRNA is substantially up-regulated following brain damage, suggesting its involvement in the pathogenesis of central nervous system injury.\(^6\) Similarly, 105 differentially expressed lncRNAs and down-regulated BC089918 and uc.217 are observed in the rat dorsal root ganglion, revealing that lncRNAs play an important role in peripheral nerve injury.\(^7\) The silencing of BC089918 and uc.217 can promote the neurite outgrowth of neurons in the dorsal root ganglion, revealing that lncRNAs play an important role in peripheral nerve injury.\(^7,8\) In addition, NONMMUG014387 lncRNA promotes the proliferation of SCs following peripheral nerve injury.\(^9\) However, the role of lncRNAs in peripheral nerve injury remains unclear, and other key lncRNAs must be explored.

The maternally expressed gene 3 (MEG3) is located in the human 14q32 chromosome, named as gene trap locus 2 in mouse, and widely investigated in tumour cases.\(^10,11\) Accumulating evidence suggests that MEG3 is a tumour-suppressing lncRNA and down-regulated in multiple malignancies.\(^12\) However, its role in peripheral nerve injury and how it modulates injured nerve regeneration remain to be clarified.

In this study, MEG3 is expressed in the SCs of rats and up-regulated after sciatic nerve transaction. Silencing MEG3 in SCs can enhance the proliferation and migration of these cells via the phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/AKT pathway and promote rat nerve regeneration and functional recovery. Thus, MEG3 may be involved in nerve injury and injured nerve regeneration in rats with sciatic nerve defects and may provide a potential therapeutic target for peripheral nerve injury.

### Materials and Methods

#### 2.1 Rat surgery

A total of 24 adult male Sprague-Dawley (SD) rats (220-230 g) were anaesthetized with xylazine and ketamine as previously described.\(^13\) The sciatic nerve at 1 cm above the bifurcation into the tibial and common fibular nerves was exposed and cut using ophthalmic scissors, and the incision was closed with 4-0 nylon sutures. The proximal stumps of the sciatic nerve from each group of animals were collected at different time points (0, 1, 4 and 7 days) after the injury. All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of Jiangsu University ( Permit Number: JSU 17-112).

#### 2.2 Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was isolated from the sciatic nerve segment by using the Trizol reagent (Invitrogen) and reverse-transcribed into cDNA by using the Prime-Script RT reagent Kit (Genecopoeia, Germantown, MD, USA). PCR was performed using the All-in-one™qPCR Mix (Genecopoeia) and the primers purchased from Genecopoeia on the ABI system (Applied Biosystems, Foster City, CA, USA) following manufacturer’s protocol. The relative expression of lncRNA MEG3 was calculated using the comparative \(2^{-\Delta\Delta Ct}\) method.

#### 2.3 Fluorescent in situ hybridization (FISH)

Cy3-labelled rat lncRNA MEG3 probes (Probe sequence: 5’-CY3-CACAGGAAGACGCGACGGGCCAGGGTA-CY3-3’) were synthesized by Servicebio. The nerve tissue sections were treated with 20 μg/mL proteinase K for 30 minutes at 37°C, and hybridization and washing were conducted as previously described.\(^14\) The MEG3 expression in the rat sciatic nerve was performed using FISH as described in a previous study.\(^15\) Briefly, Cy3-labelled MEG3 was used to detect the injured (model group) and the normal (normal group) rat sciatic nerve tissues. The negative probe was utilized as the negative control (Negative group). The images were obtained using the Nikon ECLIPSE Ci microscope (ECLIPSE Ci, Nikon, Japan). Cy3-labelled IncRNA MEG3 displayed red fluorescence, which represented the expression level of IncRNA MEG3. A high intensity indicated high MEG3 expression.

#### 2.4 Isolation and characterization of SCs

Schwann cells were isolated and cultured following a previously published protocol with slight modifications.\(^16\) The bilateral sciatic nerves and brachial plexus of 2- to 3-day-old SD rats were collected, minced, and digested with trypsin and collagenase type I.\(^16\) After digestion, the cells were cultured using the SC culture medium (ScienCell, USA) and purified with 5 μg/mL cytosine arabinoside (Sigma, USA).\(^16\)

#### 2.5 Immunofluorescence

The SCs were fixed in 4% paraformaldehyde for 30 minutes at 4°C, blocked and incubated with monoclonal anti-S100 (1:200), anti-GFAP (1:200) and anti-Ki67 (1:200, Servicebio, Wuhan, China) primary
antibodies overnight at 4°C. The Alexa Fluor 488 goat anti-rabbit (1:200, Servicebio) or Cy3 goat anti-rabbit (1:200, Servicebio) was used as the secondary antibody, and DAPI (Servicebio) was utilized to detect the nucleus. The images were obtained using an inverted fluorescence microscope (CKX-53, Olympus, Japan).

2.6 | Cell transfection

The SCs were transfected with IncRNA MEG3 siRNA with Lipofectamine RNAi MAX transfection reagent (Invitrogen, Carlsbad CA, USA) in Opti-MEM (Invitrogen) in accordance with the manufacturer’s protocol. The synthetic MEG3-siRNA and the control were purchased from Genecopoeia.

2.7 | Cell counting kit-8 (CCK-8) proliferation assay

The cell proliferation assay was performed using the CCK-8 solution (Beyotime, Nantong, China) following the manufacturer’s instructions. The SCs transfected with MEG3-siRNA or control were seeded on a 96-well plate with a SC medium. After being cultured for 48 hours, the cells were treated with CCK-8 solution for 2 hours, and the optimal density (OD) at 450 nm was measured using a microplate reader (Synergy HT, BioTek, Winooski, VT).

2.8 | Transwell migration assay

The migration capabilities of SCs were examined using the Transwell migration assay. The SCs transfected with MEG3-siRNA or control in serum-free medium (100 μL, 1 x 10^5 cells) were seeded on the upper chamber of the Transwell, and the lower chamber of the Transwell was added with complete medium (600 μL). After being cultured for 12 hours, the cells that migrated from the top chamber to the bottom surface were stained with 0.1% crystal violet. The images were obtained and counted using the ICC50 HD microscope (Leica Microsystems) and the Image J software.

2.9 | Western blot analysis

Proteins were extracted from proximal nerve tissue (5 mm long) or SCs transfected with MEG3-siRNA or control for Western blot analysis as previously described. The primary antibodies were as follows: anti-PTEN (Cell Signaling Technology, Danvers, MA, USA) (1:1000), anti-PI3K (CST, 1:1000), anti-p-PI3K (Affinity Biosciences, OH, USA) (1:1000), anti-AKT (CST, 1:1000), anti-p-AKT (CST, 1:1000), anti-S6 (CST, 1:1000), anti-p-S6 (CST, 1:1000) and β-actin (CST, 1:1000). Anti-rabbit IgG (CST, 1:2000) was used as the second antibody, and β-actin was used as the internal control.

2.10 | SC migration and axon outgrowth in vivo

The SD rat sciatic nerve injury model was constructed as previously described. The sciatic nerves were exposed and removed (3 mm) to form a 5 mm-long sciatic nerve gap between the distal and proximal nerve stumps. A silicone rubber tube was inserted into the gap. 0.2 OD (15 μL) MEG3-siRNA or control (Ribobio, Guangzhou, China) mixed with Matrigel (1:1 v/v) (BD Biosciences, Billerica, MA) was slowly injected into the conduit lumen by using a pre-cooled microsyringe in accordance with the previous description. The incision was then closed in a routine fashion. The rats were killed 15 days after the surgery, and the new nerves in the conduit lumen were harvested, embedded in paraffin and sectioned. The migration of SCs and axon outgrowth were assessed using immunofluorescence staining with anti-SOX10 (red) (Abcam, 1:500) and anti-β-Tubulin III (green) (1:100, Servicebio) antibodies.

2.11 | Walking track analysis

The model of sciatic nerve transection in rat was constructed as previously described. Walking track analysis was performed, and the sciatic function index (SFI) was measured at 7, 14, 21 and 28 days post-operation.

**FIGURE 1** Expression and localization of MEG3 in nerve tissues. A, Detection of MEG3 expression after sciatic nerve injury at 0, 1, 4 and 7 d by qRT-PCR, n = 6. B, Detection of MEG3 expression in sciatic nerve sections at 0 and 7 d after nerve injury by FISH. Negative group: negative probe; Normal group: normal rat sciatic nerve; Model group: injured rat sciatic nerve, n = 3. Scale bar = 50 μm. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01
post-neurorrhaphy based on the basis of a previously described protocol.

2.12 | Statistical analysis

All data were presented as mean ± standard error of the mean (SEM). Statistical analyses were performed using Student’s t test by using the GraphPad Prism V 5.0 (GraphPad, San Diego, CA, USA). $P < 0.05$ was regarded as statistically significant.

3 | RESULTS

3.1 | IncRNA MEG3 expression is up-regulated after sciatic nerve injury

Rat sciatic nerve segments were collected for MEG3 analysis by qRT-PCR to evaluate the MEG3 expression after sciatic nerve injury. As shown in Figure 1A, the MEG3 expression has remarkably increased at days 4 and 7 after sciatic nerve injury compared with that at day 0 (control) and reached its peak on the seventh day (Figure 1A). In situ hybridization has further revealed that MEG3 expression in SCs and that MEG3 is significantly up-regulated on the seventh day after sciatic nerve injury (Figure 1B).

3.2 | Localization of IncRNA MEG3 in SCs

Primary SCs were isolated and cultured to detect and verify the MEG3 expression in SCs through the FISH experiment. As shown in Figure 2A, adherent cells display long spindle-like shapes after 1 day of initial culture (Figure 2Ai) and show uniform morphology after the purification of the fourth generation (Figure 2Aii). S-100 and GFAP are considered as identification markers of SCs. As shown in Figure 2B, almost all cells are S-100- and GFAP-positive, indicating that the extracted cells are SCs. The FISH experiment reveals that MEG3 is localized in the SC cytoplasm (Figure 2C).

3.3 | IncRNA MEG3 knockdown promotes SC proliferation and migration by regulating the PTEN/PI3K/AKT pathway

The silencing of MEG3 was performed by transfecting specific siRNAs into SCs to further investigate the role of MEG3 in SCs.
FIGURE 3  MEG3 affects the proliferation and migration of SCs. A, Specific MEG3-siRNAs decrease MEG3 expression in SCs as detected by qRT-PCR. B, CCK8 analysis of SC proliferation after transfection with MEG3-siRNAs. C, Representative images (left) and quantification data (right) of Ki67 staining (red). Nuclei were stained with DAPI (blue), n = 5. D, Representative images (left) and quantification data (right) of Transwell migration assay, n = 5. Values are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

FIGURE 4  MEG3 regulates the PTEN/PI3K/AKT signalling in primary SCs. Western blot analysis of PTEN, p-PI3K, PI3K, p-AKT, AKT, p-S6 and S6 expression levels after MEG3 siRNA transfection in SCs. A, Representative blot. B, Bar graph of the relative expression level of proteins. Values are obtained from three independent experiments and presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
Figure 3A illustrates that siRNA1 and siRNA2 have significantly decreased the mRNA expression of MEG3 compared with the NC control. After transfection for 48 hours, the cell proliferation assay shows that the group subjected to MEG3 knockdown can noticeably promote SC proliferation compared with that in the control group (Figure 3B). Ki67 staining has further revealed that MEG3 silencing promotes SC proliferation (Figure 3C). Furthermore, MEG3 down-regulation can promote the migration of SCs, as indicated by the Transwell migration assay (Figure 3D).

The PTEN/PI3K/AKT signalling regulates cell proliferation and migration. Thus, the PTEN/PI3K/AKT pathway was used to investigate whether the promotion of SC proliferation and migration was mediated by MEG3 knockdown. The expression of signal molecules in SCs after being transfected with MEG3-siRNA or control for 48 hours was examined by Western blot analysis. As shown in Figure 4, the MEG3 siRNA transfection down-regulates the expression of PTEN but up-regulates those of p-PI3K, p-AKT and p-S6 relative to those in the NC control (Figure 4A,B). These results suggest that MEG3 knockdown promotes SC proliferation and migration by regulating the PTEN/PI3K/AKT pathway.

3.4 | IncRNA MEG3 knockdown promotes SC proliferation and migration and axon outgrowth in vivo

A rat sciatic nerve injury model was established to determine whether MEG3 can also regulate SC migration in vivo, and a silicone-based nerve guidance conduit was administered to the specific MEG3-siRNA and control groups. The SCs were detected by immunostaining for the specific marker SOX10 in the longitudinal sections of the regenerated sciatic nerves 18 days after surgery. As shown in Figure 5A and 5B, the MEG3 siRNA injection significantly promotes the proliferation and migration of SCs because of the increased...
distance of the migrated SCs in the MEG3 siRNA injection group. By contrast, the SCs from the control group have a short migration distance, and the proximal and distal nerves are not connected in sections. Moreover, MEG3 siRNA injection significantly promotes axonal regeneration because the β-tubulin III expression in the group injected with MEG3 siRNA is significantly up-regulated compared with that in the NC control group. This finding suggests that MEG3 siRNA injection increases the distance of axon outgrowth in rats with sciatic nerve injury (Figure 5C,D). These results suggest that MEG3 knockdown can promote nerve injury regeneration by regulating the proliferation and migration of SCs in vivo.

3.5 | IncRNA MEG3 knockdown promotes the functional recovery of the sciatic nerve through regulating the PTEN/PI3K/AKT signalling

MEG3 regulates SC proliferation and migration and facilitates nerve regeneration. We further investigated whether its knockdown affects the functional recovery in rats after sciatic nerve transection. Walking track analysis and SFI were used to evaluate the functional recovery. As shown in Figure 6, the typical working tracks indicate an apparent improvement in MEG3 siRNA-injected rats at 14 days after surgery. Similarly, the group injected with MEG3 siRNAs has significantly improved the SFI at 14 days after surgery compared with that in the NC control group (Figure 6B). The group injected with MEG3 siRNA has down-regulated PTEN expression levels and up-regulated p-PI3K, p-AKT and p-S6 expression levels relative to those in the NC control group (Figure 7). These results are consistent with the finding that MEG3 regulates the proliferation and migration of SCs in vitro (Figure 4). Moreover, these results indicate that the knockdown of IncRNA MEG3 facilitates the functional recovery of the severed sciatic nerve by regulating the PTEN/PI3K/AKT pathway.

4 | DISCUSSION

The proliferation and migration of SCs play a key role in peripheral nerve injury, provide trophic support to axons, and contribute to the development and regeneration of injured nerves. Inhibiting SC proliferation and migration by using local mitomycin can substantially decrease the axonal regeneration in rat sciatic nerve injury. Thus, exploring the regulatory mechanism of SCs is important for peripheral nerve injury therapy. IncRNAs are involved in nerve injury recovery by regulating the PTEN/PI3K/AKT pathway.
injury and regeneration.\(^5^7\) Yao and colleagues reported that IncRNA TNXA-PS1 modulates SCs by sponging miR-24-3p/miR-152-3p, thereby affecting the expression of dual-specifity phosphatase1 and nerve regeneration in rat sciatic nerve injury.\(^1^6\) However, some roles of IncRNA in peripheral nerve injury are still unknown. In the present study, IncRNA MEG3 can affect nerve regeneration in a sciatic nerve transected rat by regulating the proliferation and migration of SCs in vitro and in vivo.

As a tumour suppressor gene, IncRNA MEG3 is the focus of tumour investigations and can inhibit the proliferation and metastasis of various tumour cells, including breast, lung, glioma, cervical, gastric and liver cancer cells.\(^2^1^,^2^2\) This gene participates in neuropathological changes and nerve damage. Yi and colleagues reported that MEG3 expression is down-regulated in the hippocampus tissues of rats with Alzheimer’s disease (AD), and its up-regulation can alleviate neuronal damage and improve the functional recovery via the PI3K/AKT signalling pathway.\(^2^3\) MEG3 expression is increased in patients with subarachnoid haemorrhage relative to that in healthy controls and participates in the SAH-induced neuronal cell injury.\(^2^4\) However, the role of MEG3 in peripheral nerve damage and regeneration has not been reported.

In this study, the expression of IncRNA MEG3 is up-regulated at 4 days and reached its peak 7 days after sciatic nerve injury. Moreover, the IncRNA MEG3 is expressed in SCs. Sciatic nerve injury can elicit transcriptional alteration.\(^2^5\) The time point of MEG3 up-regulation shows a similar pattern to that of the expression of immune response genes, which are up-regulated between 3 and 7 days following nerve crush injury and have peaked 7 days post-crush.\(^2^6\) Results suggest that the IncRNA MEG3 participates in nerve injury and regeneration by regulating the proliferation and migration of SCs. These cells supplement the defective tissues through proliferation and migration and favour the axonal outgrowth and nerve regeneration following peripheral nerve injury.\(^2^7\) The primary SCs were cultured, and the localization of MEG3 in the SC cytoplasm was verified (Figure 2). Silencing IncRNA MEG3 improves the SC proliferation and migration via the PTEN/PI3K/AKT pathway (Figures 3 and 4). Notably, the peripheral nerve injury is often accompanied by ROS and inflammation, resulting in the accumulation of reactive oxygen species (ROS).\(^2^8\) Aggregated ROS and inflammation have been reported to cause MEG3 up-regulation in rats with cirrhotic neuropathy\(^2^9\) and UVB-induced murine skin lesions.\(^1^5\) The knockdown of MEG3 improves the SC proliferation and migration and nerve function recovery in rats. This result is consistent with the observations that down-regulated MEG3 expression protects against sciatic nerve injury in cirrhotic rats\(^3^0\) and UVB-induced skin lesions in mice.\(^1^5\) Thus, the increase of IncRNA-MEG3 at 7 days after sciatic nerve injury may be due to ROS and inflammatory factors produced after injury, but the mechanism needs further analysis.

After peripheral nerve injury, neurons activate regenerative or cell death signalling pathways, which may influence the injured neurons to regenerate or die.\(^3^0\) PTEN plays an important role in central axon growth as a negative regulator of the PI3K pathway,\(^3^1\) and its inhibition by using a specific PTEN phosphatase inhibitor or PTEN siRNA at the injury site facilitates peripheral nerve regeneration by accelerating axon outgrowth.\(^3^2\) Furthermore, the activation of the PI3K/Akt pathway promotes axon growth.\(^3^3\) The PI3K pathway activation in neurons by the exogenous growth factors or knockout of PTEN promotes neurite growth and elongation.\(^3^4^,^3^5\) Consistent with the above report, MEG3 knockdown has down-regulated the expression of PTEN, up-regulated those of p-PI3K, p-AKT and p-S6, and promoted SC proliferation and migration, axon outgrowth and the functional recovery of the injured sciatic nerves in rats (Figure 6). These results are also consistent with the role of MEG3 in cancer and AD. The overexpression of MEG3 inhibits endometrial cancer cell proliferation, invasion and metastasis via the PI3K pathway.\(^3^6\) Increased MEG3 expression inactivates the PI3/Akt pathway in the hippocampus tissues of rats with AD.\(^2^3\) IncRNAs also exert their regulatory role by sponging miRNA. IncRNA MEG3 sponges miR-494 to inhibit haemangioma tumorigenesis by regulating the PTEN/PI3K/AKT pathway.\(^3^7\) The competitive binding of MEG3 and miR-1297 to the 3'-UTR of PTEN regulates the progression of testicular germ cell tumours via the PTEN/PI3K/AKT pathway.\(^3^8\) Thus, IncRNA MEG3 is inferred to participate in nerve repair and regeneration by regulating the proliferation and migration of SCs via the PTEN/PI3K/AKT signalling. However, the role of IncRNA MEG3 in neural injury needs to be further investigated to actively explore IncRNA- or ncRNA-based therapies for peripheral nerve regeneration.

In summary, this study has revealed that IncRNA MEG3 regulates SC proliferation and migration in vitro and in vivo and participates in the nerve regeneration and functional recovery in sciatic nerve-transected rats. Our findings suggest that MEG3 or other IncRNAs may be a promising therapeutic target for peripheral nerve injury.

ACKNOWLEDGEMENTS
This work was supported by a grant from the National Natural Science Foundation of China (81871243, 81900562), the key research and development programs of Jiangsu Province (BE2017697), the Six Talent Peaks of Jiangsu Province (WSN-009), Jiangsu Provincial Medical Innovation Team (CXTDC2016009), Key Medical Personnel of Zhenjiang (2014), ‘LiuGeYi’ Projects of Jiangsu Province (LGY2016055), ‘XueDiJiFang’ Projects of Jiangsu Province (x201812), the Affiliated Hospital of Jiangsu University (jdfyRC2015010) and the Science and Technology Plan Project of Changzhou (CJ20180001).

CONFLICT OF INTEREST
The authors declare that they have no competing interests. The funding agencies played no role in the design or implementation of the study, analysis or interpretation of the data, or the preparation and submission of the manuscript.

AUTHOR CONTRIBUTIONS
YBM, LYD and XFW conceived and designed the experiments. YBM, DWZ, WZZ, HYZ, LYD and ZY performed the experiments. YBM, LYD, DQF, YPZ YZ and TW analysed the data. CMM and XFW
contributed reagents/materials/analysis tools. YBM and XFW wrote the paper. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in [repository name e.g. ‘figshare’] at http://doi.org/[doi], reference number [reference number].

ORCID
Xuefeng Wang https://orcid.org/0000-0002-5980-6530

REFERENCES
1. Gordon T, Eva P, Borschel GH. Delayed peripheral nerve repair: methods, including surgical ‘cross-bridging’ to promote nerve regeneration. *Neural Regen Res*. 2015;10:1540-1544.
2. Bamba R, Riley DC, Kelm ND, Does MD, Dortch RD, Thayer WP. A novel technique using hydrophilic polymers to promote axonal fusion. *Neural Regen Res*. 2016;11:525-528.
3. Freidin M, Asche S, Bargiello TA, Bennett MV, Abrams CK. Connexin 32 increases the proliferative response of Schwann cells to neuregulin-1 (Nrg1). *Proc Natl Acad Sci USA*. 2009;106:3567-3572.
4. Al-Zer H, Kalbouneh H. Dental pulp stem cells-derived schwann cells for peripheral nerve injury regeneration. *Neural Regen Res*. 2015;10:1945-1946.
5. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. *J Cell Mol Med*. 2000;10:1711-1718.
6. Zhao F, Qu Y, Liu J, et al. Microarray profiling and co-expression network analysis identifies lncRNA Meg3 activates inflammatory damage in dorsal root ganglion after rat sciatic nerve injury. *Neurosci Lett*. 2013;534:117-122.
7. Yao C, Wang J, Zhang H, et al. Long non-coding RNA uc.217 regulates neurite outgrowth in dorsal root ganglion neurons following peripheral nerve injury. *Eur J Neurosci*. 2015;42:1718-1725.
8. Pan B, Shi ZJ, Yan JY, Li JH, Feng SQ. Long non-coding RNA NONMMUG014387 promotes Schwann cell proliferation after peripheral nerve injury. *Neural Regen Res*. 2017;12:2084-2091.
9. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell*. 2011;43:904-914.
10. Wylie AA, Murphy SK, Orton TC, Jirtle RL. Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. *Genome Res*. 2000;10:1711-1718.
11. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. *J Mol Endocrinol*. 2012;48:R45-53.
12. Ma Y, Dong L, Zhou D, et al. Extracellular vesicles from human umbilical cord mesenchymal stem cells improve nerve regeneration after sciatic nerve transection in rats. *J Cell Mol Med*. 2019;23:2822-2835.
13. Yao C, Wang Y, Zhang H, et al. IncRNA TNXA-PS1 modulates Schwann cells by functioning as a competing endogenous RNA following nerve injury. *J Neurosci*. 2018;38:6574-6585.
14. Zhang N, Zhong Z, Wang Y, et al. Competing endogenous network analysis identifies IncRNA Meg3 activates inflammatory damage in UBV induced murine skin lesion by sponging miR-93-5p/epiregulin axis. *Aging*. 2019;11:10664-10683.
15. Yuan H, Zhang J, Liu H, Li Z. The protective effects of resveratrol on Schwann cells with toxicity induced by ethanol in vitro. *Neurochem Int*. 2013;63:146-153.
16. Zhu H, Xue C, Yao M, et al. miR-129 controls axonal regeneration via regulating insulin-like growth factor-1 in peripheral nerve injury. *Cell Death Dis*. 2018;9:720.
17. Jiang Y, Chang H, Chen G. Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/Pi3K/AKT signaling pathway. *Oncology letters*. 2018;15:10001-10007.
18. Ling C, Wang X, Zhu J, et al. MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the Pi3K/Akt pathway in non-small cell lung cancer. *Cancer Med*. 2019;8:3520-3531.
19. Hoke A. Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans? *Nat Clin Pract Neurol*. 2006;2:448-454.
20. Ali-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. *Pathol Oncol Res: POR*. 2019;25:859-874.
21. Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. *Biomed Pharmacother*. 2019;118:109129.
22. Li S, Liu Q, Wang Y, et al. Differential gene expression profiling and biological process analysis in proximal nerve segments after sciatic nerve transection. *PLoS ONE*. 2013;8:e57000.
23. Pannirselvam S, Napoli I, Ribeiro S, et al. EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting. *Cell*. 2010;143:145-155.
24. Lu Y, Li R, Zhu J, et al. Fibroblast growth factor 21 facilitates peripheral nerve regeneration through suppressing oxidative damage and autophagic cell death. *J Cell Mol Med*. 2019;23:497-511.
25. Mohamed DI, Khairy E, Khedr SA, Habib EK, Elayat WM, El-Kharaishy OA. N-acetylcysteine (NAC) alleviates the peripheral neuropathy associated with liver cirrhosis via modulation of neural MEG3/PAR2/ NF-B axis. *Neurochem Int*. 2020;132:104602.
26. Terenghi G, Hart A, Wiberg M. The nerve injury and the dying neurons: diagnosis and prevention. *J Hand Surg Eur Vol*. 2011;36:730-734.
27. Park KK, Liu K, Hu Y, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. *Science*. 2008;322:963-966.
28. Christie KJ, Webber CA, Martinez JA, Singh B, Zochodne DW. PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. *J Neurosci*. 2010;30:9306-9315.
29. Korhonen JM, Said FA, Wong AJ, Kaplan DR. Gab1 mediates neurite outgrowth, DNA synthesis, and survival in PC12 cells. *J Biol Chem*. 1999;274:37307-37314.
30. Jones DM, Tucker BA, Rahimtula M, Mearow KM. The synergistic effects of NGF and IGF-1 on neurite growth in adult sensory neurons: convergence on the PI 3-kinase signaling pathway. *J Neurochem*. 2003;86:1116-1128.
31. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. *J Natl Cancer Inst*. 1999;91:1922-1932.
36. Sun KX, Wu DD, Chen S, Zhao Y, Zong ZH. LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. *Apoptosis*. 2017;22:1543-1552.

37. Dai Y, Wan Y, Qiu M, et al. LncRNA MEG3 suppresses the tumorigenesis of hemangioma by sponging miR-494 and regulating PTEN/PI3K/AKT pathway. *Cell Physiol Biochem*. 2018;51:2872-2886.

38. Yang NQ, Luo XJ, Zhang J, Wang GM, Guo JM. Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. *Am J Transl Res*. 2016;8:1091-1099.

How to cite this article: Ma Y, Zhai D, Zhang W, et al. Down-regulation of long non-coding RNA MEG3 promotes Schwann cell proliferation and migration and repairs sciatic nerve injury in rats. *J Cell Mol Med*. 2020;24:7460–7469. [https://doi.org/10.1111/jcmm.15368](https://doi.org/10.1111/jcmm.15368)